|
Palo Alto, CA,
May
1, 2006 — Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Deutsche Bank 2006 Health Care Conference in Boston on May 2, 2006 at 9:00 a.m. Eastern time. A webcast of the presentation will be available via the Deutsche Bank website, www.corporate- ir.net/media_files/event/2006/May/DeutscheBankHealthcare/Agenda/050206.htm.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA® (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA™ (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
